alveolar soft part sarcoma (Cancer)
Information
- Disease name
- alveolar soft part sarcoma
- Disease ID
- DOID:4239
- Description
- "A soft tissue cancer that is a slow growing tumor of an unknown origin that effects children and effects young adults." [url:http\://en.wikipedia.org/wiki/Alveolar_soft_part_sarcoma]
Disease area statistics
Chromosome band
| Gene symbol | Chromosome | Start | Stop | The number of variant |
|---|---|---|---|---|
| ASPSCR1 | 17 | 81,977,550 | 82,017,404 | 2 |
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT02180867 | Active, not recruiting | Phase 2/Phase 3 | Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery | July 11, 2014 | December 22, 2024 |
| NCT02867592 | Active, not recruiting | Phase 2 | Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors | May 18, 2017 | September 21, 2024 |
| NCT03016819 | Active, not recruiting | Phase 3 | Phase III Trial of Anlotinib, Catequentinib in Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma, Synovial Sarcoma (APROMISS) | August 15, 2017 | June 2025 |
| NCT00340353 | Completed | Collection of Alveolar Soft Part Sarcoma and Blood Specimens for Research | April 7, 2005 | April 12, 2012 | |
| NCT02636725 | Completed | Phase 2 | Axitinib and Pembrolizumab in Subjects With Advanced Alveolar Soft Part Sarcoma and Other Soft Tissue Sarcomas | April 19, 2016 | March 3, 2023 |
| NCT04999761 | Recruiting | Phase 1 | AB122 Platform Study | June 1, 2021 | May 2026 |
| NCT03967834 | Recruiting | N/A | Multimodal Immune Characterization of RAre Soft Tissue Sarcoma - MIRAS Project From SARRA (SARcome RAre) Project of the French Sarcoma Group | April 26, 2021 | April 2031 |
| NCT04332874 | Recruiting | Phase 2 | A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or Leg | April 1, 2020 | April 1, 2025 |
| NCT03989596 | Unknown status | Phase 2 | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas | June 1, 2018 | December 31, 2022 |
| NCT03623581 | Unknown status | Phase 2 | Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226) | September 6, 2018 | December 30, 2022 |
| NCT03880123 | Withdrawn | Phase 1 | Selinexor in Combination With Ixazomib for the Treatment of Advanced Sarcoma | November 2020 | November 24, 2020 |
- Disase is a (Disease Ontology)
- DOID:4043
- Cross Reference ID (Disease Ontology)
- GARD:5654
- Cross Reference ID (Disease Ontology)
- ICDO:9581/3
- Cross Reference ID (Disease Ontology)
- MESH:D018234
- Cross Reference ID (Disease Ontology)
- MIM:606243
- Cross Reference ID (Disease Ontology)
- NCI:C3750
- Cross Reference ID (Disease Ontology)
- NCI:C7943
- Cross Reference ID (Disease Ontology)
- NCI:C8092
- Cross Reference ID (Disease Ontology)
- ORDO:163699
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:88195001
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0206657
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0279544
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0279985
- HPO Human Phenotype ID (Human Phenotype Ontology)
- HP:0012218